S&P 500

5.308,13

0,00%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Halozyme Therapeutics Incorporated (HALO)
Halozyme Therapeutics Incorporated (HALO) Notícias

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:HALO

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
21/05/2024	08:15	PR Newswire (US)	Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®	NASDAQ:HALO	Halozyme Therapeutics Incorporated
08/05/2024	09:30	PR Newswire (US)	Halozyme to Participate in Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
07/05/2024	17:09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
07/05/2024	17:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HALO	Halozyme Therapeutics Incorporated
07/05/2024	17:01	PR Newswire (US)	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
25/04/2024	17:45	PR Newswire (US)	Mahesh Krishnan Elected to Halozyme's Board of Directors	NASDAQ:HALO	Halozyme Therapeutics Incorporated
23/04/2024	09:30	PR Newswire (US)	Halozyme to Report First Quarter 2024 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
04/03/2024	18:13	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:HALO	Halozyme Therapeutics Incorporated
28/02/2024	20:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
28/02/2024	18:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:HALO	Halozyme Therapeutics Incorporated
20/02/2024	18:07	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
20/02/2024	18:01	PR Newswire (US)	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
12/02/2024	08:19	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:HALO	Halozyme Therapeutics Incorporated
08/02/2024	18:30	PR Newswire (US)	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
29/01/2024	18:15	PR Newswire (US)	Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	NASDAQ:HALO	Halozyme Therapeutics Incorporated
18/01/2024	10:30	PR Newswire (US)	Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis	NASDAQ:HALO	Halozyme Therapeutics Incorporated
16/01/2024	10:15	PR Newswire (US)	Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	NASDAQ:HALO	Halozyme Therapeutics Incorporated
16/01/2024	03:15	PR Newswire (US)	Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types	NASDAQ:HALO	Halozyme Therapeutics Incorporated
12/01/2024	11:25	PR Newswire (US)	Halozyme to Host Investor Business Forum and Long-Term Outlook Call	NASDAQ:HALO	Halozyme Therapeutics Incorporated
27/11/2023	10:00	PR Newswire (US)	Halozyme to Present at Upcoming Investor Conferences	NASDAQ:HALO	Halozyme Therapeutics Incorporated
16/11/2023	11:00	PR Newswire (US)	Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis	NASDAQ:HALO	Halozyme Therapeutics Incorporated
06/11/2023	18:01	PR Newswire (US)	HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
06/11/2023	09:30	PR Newswire (US)	Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease	NASDAQ:HALO	Halozyme Therapeutics Incorporated
30/10/2023	19:35	PR Newswire (US)	Halozyme To Report Third Quarter 2023 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated
19/10/2023	08:15	PR Newswire (US)	Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma	NASDAQ:HALO	Halozyme Therapeutics Incorporated
16/10/2023	16:05	PR Newswire (US)	Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference	NASDAQ:HALO	Halozyme Therapeutics Incorporated
16/10/2023	09:00	PR Newswire (US)	Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery	NASDAQ:HALO	Halozyme Therapeutics Incorporated
29/08/2023	05:50	PR Newswire (US)	Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain	NASDAQ:HALO	Halozyme Therapeutics Incorporated
08/08/2023	17:01	PR Newswire (US)	HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS	NASDAQ:HALO	Halozyme Therapeutics Incorporated
25/07/2023	09:30	PR Newswire (US)	Halozyme To Report Second Quarter 2023 Financial and Operating Results	NASDAQ:HALO	Halozyme Therapeutics Incorporated